An insightful webinar on our actively managed ARK Genomic Revolution Strategy, uncovering how breakthroughs in genomics and multiomic technologies are transforming healthcare and extending the quality of life.
In 2023, the medical community achieved a milestone with the first approvals for gene editing treatments for beta thalassemia and sickle cell disease in both the United States and Europe, signaling a new dawn for patients burdened by these conditions. Meanwhile, in the UK in 2022, a young leukemia patient found hope through a pioneering T-cell therapy, marking another step forward in our battle against cancer.
In this webinar, we explore the latest milestones in gene editing and pioneering therapies that offer new hope for genetic disorders and cancer. We highlight companies in our Genomic Revolution portfolio that are driving advances in diagnostics, vaccines, and therapeutics, providing targeted responses to rare diseases like cancer, cystic fibrosis, HIV, and certain types of leukemia. This fund represents a shift from reactive sick-care to proactive healthcare, emphasising prevention. Join us to discover how this revolution has the potential to reshape medicine as we know it.
Webinar recorded on 26th June 2024.
